Alessandra Camarca


Alessandra Camarca


Direct: +39 0825 299361
FAX: +39 0825 781585
Personal Web Site:

Short CV

Research Interests

Dr. Camarca is an expert in mucosal immunology and in particular in the mechanisms leading to gluten-induced enteropathy (Coeliac Disease). She has special expertises in gluten immunogenic sequences and in cellular biology of gluten-specific mucosal T-lymphocytes. For several years her main interests have been to identify the repertoire of gluten epitopes active in the majority of celiac disease patients, to study the regulatory mechanisms leading to a down-regulation of the anti-gluten T cell response and to address the role of cytotoxic T lymphocytes in the gluten induced inflammation. She has also contributed to several works aiming to search alternative cereals at low toxicity for celiac disease patients, and to validate enzymatic strategies for gluten detoxification. Technical skills of Dr. Camarca involve the in vitro expansion and culturing of primary intestinal gluten-specific T cell lines, cellular immunology assays and cytofluorimetric analysis.

She recently joined the group of Dr. D’Auria, where she will apply advanced fluorescence and label-free techniques to study molecular immunology.

Key Publications


Gianfrani C, Camarca A, Mazzarella G et al. Extensive in vitro gastrointestinal digestion markedly reduces the immune-toxicity of Triticum monococcum wheat: Implication for celiac disease. Mol Nutr Food Res. 2015

Lamacchia C, Camarca A, Picascia S, Di Luccia A, Gianfrani C. Cereal-based gluten-free food: how to reconcile nutritional and technological properties of wheat proteins with safety for celiac disease patients. Nutrients. 2014 Jan 29;6(2):575-90.

Camarca A, Radano G, Di Mase R et al. Reproducibility of the in vivo short wheat challenge, a sensitive tool to monitor immune responsiveness to gluten. Clin Exp Immunol. 2012 Aug;169(2):129-36.

Camarca A, Del Mastro A and Gianfrani C. Repertoire of gluten peptides active in celiac disease patients: perspectives for translational therapeutic applications. Endocr Metab Immune Disord Drug Targets. 2012 Jun;12(2):207-19. Review.

Mamone G*, Camarca A*, Fierro O, Sidney J, Mazzarella G, Addeo F, Auricchio S, Troncone R, Sette A, Gianfrani C. Immunogenic peptides can be detected in whole gluten by transamidating highly susceptible glutamine residues: implication for searching of gluten-free cereals. J Agric Food Chem. 2012 Dec 18.

Camarca A, Anderson RP, Mamone G, Fierro O, Facchiano A, Costantini S, Zanzi D, Sidney J, Auricchio S, Sette A, Troncone R and Gianfrani C. Intestinal T-cell responses to gluten peptides are largely heterogeneous: implication for a peptide-based therapy in celiac disease. J. Immunol. 2009 182: 4158-4166.

Mazzarella G, Stefanile R, Camarca A, Giliberti P, Casentini E, Marano C, Iaquinto G, Giardullo N, Auricchio S, Sette A, Troncone R, Gianfrani C. Gliadin activates HLA class I-restricted CD8+ T-cells in coeliac intestinal mucosa and induces the enterocyte apoptosis. Gastroenetrology 2008;134:1017–1027.

Gianfrani C, Siciliano RA, Facchiano AM, Camarca A, Mazzeo MF, Costantini S, Salvati V, Maurano F, Mazzarella G, Iaquinto G and Rossi M. Transamidation inhibits the intestinal immune response to gliadin in vitro. Gastroenterology 2007; 133:780-789.

Research Group

Dr. Sabato D’Auria

Research area: OMICS